also recommended alongside these treatments. 2, [9] [10] [11] Emollients improve skin hydration, help to restore the lipid balance of the skin, and may reduce penetration by irritants. 12, 13 They also help relieve inflammation and itching. 12, 14 However, most emollients are cosmetic products indicated only for healthy skin and should not be applied to skin lesions. 14 In contrast, medical device repairing emollient creams (MDRECs) are suitable for treating damaged skin. MDRECs are specifically designed to improve skin hydration and provide a physical shield to help restore the skin's barrier function. Because their primary action is usually mechanical, some MDRECs are considered class II medical devices according to European legislation. 15 Only a few clinical studies have investigated the tolerability and effectiveness of emollients for managing CHD. 14 Furthermore, studies rarely evaluate their acceptability, which can affect patient compliance.
Dexyane MeD ® (Laboratoires Dermatologiques Ducray, Pierre
Fabre, France) is a MDREC containing a natural polysaccharide mesh that protects and hydrates the skin. This MDREC is a class II medical device designed to repair and protect the skin barrier for individuals ≥3 months of age. Here, we report the results of a study investigating the tolerability and benefit of this MDREC in adults with mild-tomoderate CHD.
| MATERIALS AND METHODS

| Study design
This was an open-label, single-center study conducted in Gdansk, Poland, between March and May 2015. The primary objective was to assess the local tolerability of the MDREC (Dexyane MeD) applied twice daily for 3 weeks in adults with mild-to-moderate CHD. Secondary objectives were to assess the local tolerability immediately after first application and after 1 week of twice daily application, the global tolerability after 3 weeks of twice daily application considering any reactions reported during the study, the efficacy in improving signs and symptoms of CHD, subject quality of life, and overall subject satis- 
| Study conduct
Subjects were instructed to apply the MDREC on both hands twice daily (morning and evening) every day for 3 weeks, even if their lesions had healed. Subjects were instructed to maintain their usual body and hand hygiene routine, but could not apply their usual hand care product. In addition, subjects could not apply any skincare product on their hands (including the MDREC) within 2 hours of each visit and could not wash their hands within 2 hours of applying the MDREC. Subjects were to keep a daily record of MDREC application detailing any omissions, changes in application frequency, skin reactions following application, whether they were taking other treatments or applying other products, and how lesions responded.
| Tolerability and safety assessments
The primary outcome measure was the local tolerability of the MDREC on the hands at the end of the study ( 
| Efficacy assessments
Investigators assessed efficacy using the modified total lesion symptom score (mTLSS) and an IGA score on days 1 (before first THOUVENIN ET AL. 
| Study size estimation
Statisticians estimated a sample size of at least 35 subjects was required to evaluate possible adverse effects and tolerability related to the MDREC in adults with CHD. To account for possible dropouts, 40 subjects were to be included.
| Statistical analysis
Analyses were performed for all subjects receiving at least one dose of MDREC. Differences in efficacy compared with baseline were determined by Wilcoxon matched-pairs signed-rank test or paired t test. Missing data were not replaced unless a subject withdrew from the study due to poor tolerability, in which case the missing data were replaced with the worst case (bad tolerability) for the primary outcome measure. Statistical analysis was performed using SAS® version 9.3 (SAS Institute, Cary, NC, USA). All statistical tests were 2-tailed with a type-I error of 0.05.
| RESULTS
| Subjects
This study was conducted between March 11 and May 19, 2015 and included 40 subjects, all of which completed the study. Most subjects were female (77.5%), and the median age was 32.4 years ( 
| Safety
At least one AE related to the MDREC was reported in 25 subjects (62.5%). The most common AE was burning or warm sensations reported in 19 subjects (47.5%), followed by stinging in 15 subjects (37.5%), erythema in 13 subjects (32.5%), and itching in eight patients (20.0%). Most AEs were mild or moderate in severity and most occurred within the first week of treatment, typically on the day of the first application. Almost all AEs were transient, frequently lasting <30 minutes, and none led to premature withdrawal from the study, modification of MDREC application, or corrective treatment.
No serious AEs were reported. | 1161 study progressed (Figures 1 and 2) . Accordingly, as measured by the total mTLSS, lesions were less severe than at baseline at both Day 8
| Efficacy
(mean change ± SD, −3.9 ± 2.1 [−47%]; P < 0.001) and Day 22
(−4.8 ± 2.7 [−58%]; P < 0.001). CHD severity, as assessed by IGA scores, was significantly decreased at Day 22 compared to baseline and improved in 65.0% of the subjects (Table 3) , to the extent that CHD had cleared or almost cleared in half of the subjects by the end of the study.
In agreement with the investigators' findings, most subjects (85.0% at days 8, 15, and 22) reported that their CHD had improved from baseline (Table 4) . Moreover, 12.5% (n = 5) at Day 15% and 17.5% (n = 7) at Day 22 reported that their CHD had totally resolved. Subjects also reported that, at days 8, 15, and 22, pain intensity had significantly decreased from baseline (−73% at Day 8, −80% at Day 15, −78% at Day 22; P < 0.001) as had pruritus intensity (−58% at Day 8, −71% at Day 15, −70% at Day 22; P < 0.001).
Furthermore, at days 8 and 22, they reported that their quality of life had significantly improved from baseline.
| Satisfaction with the MDREC
The mean satisfaction score, assessed on a 10-point scale, was 7.2 ± 2.4 (mean ± SD) and 82% (32/39) of subjects assigned a score ≥5. Subjects were generally satisfied with the MDREC's application and texture, reporting it as not overly greasy, sticky, or slippery.
Most subjects reported that their skin appeared healthy and less irritated after using the product and that the product favored the disappearance of eczema lesions. In addition, 72% (28/39) of subjects also reported the product as more effective than their usual emollient cream.
| DISCUSSION
The benefit of emollients has been widely demonstrated for treating atopic dermatitis, but only a few studies have investigated their efficacy in CHD. 12, 14, 17 This study showed that a MDREC, Dexyane MeD, applied twice daily for 3 weeks, was well tolerated in adults with mild-to-moderate CHD. Additionally, investigators and subjects reported that the signs and symptoms of CHD decreased during the study, and subjects reported their quality of life had improved.
As the study progressed, the number of subjects rating local tolerability as excellent increased. This likely reflects skin lesion healing and improved skin barrier function due to the hydrating and protective qualities of emollients. 12, 13 The most frequent AEs reported by subjects were mild, transient burning or warm sensations, stinging, and erythema during the first days of application. Similar mild discomfort has been observed for emollient treatments for atopic dermatitis, 12, 20, 21 which is not surprising because defects in the cutaneous barrier can make the skin sensitive.
1,2
Because this was not a controlled trial, the extent to which the MDREC improved CHD is unclear. Nonetheless, similar decreases in the signs and symptoms of CHD have been observed in other studies of emollient treatment. One study showed that twice daily application of emollients for 2 months reduced CHD symptom severity, as indicated by IGA scores and patient assessments. 17 A randomized study of subjects with controlled CHD also showed that regular emollient use prolongs the time to relapse. 14 Vesiculation and edema did not significantly decrease during our study, probably because these symptoms were present in only a few subjects.
Individuals with CHD are less likely to use emollients that are thick or greasy or that have other unpleasant cosmetic properties.
Acceptability is important because individuals with CHD often do not adhere to daily treatment recommendations 7, 22 and therefore may suffer more frequent relapse. 14 Most subjects in the study liked the product and preferred it to their current emollient cream. Moreover, subjects were generally satisfied with the product's texture, reporting it as not overly greasy, sticky, or slippery.
In conclusion, this study showed that this MDREC was well tolerated and beneficial for managing mild-to-moderate CHD. Its very good acceptability suggests that individuals with CHD will be comfortable to use it as part of their daily treatment. Agnieszka Cegielska, Beata Imko-Walczuk, Ewa Mielewczyk, Aleksandra Okuniewska, and Joanna Garstecka, for recruiting and evaluating the patients.
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